-
1Academic Journal
Συγγραφείς: V. Grünwald, T. Powles, M. Eto, E. Kopyltsov, S. Y. Rha, C. Porta, R. Motzer, T. E. Hutson, M. J. Méndez-Vidal, S. H. Hong, E. Winquist, J. C. Goh, P. Maroto, T. Buchler, T. Takagi, J. E. Burgents, R. Perini, C. He, C. E. Okpara, J. McKenzie, T. K. Choueiri
Συνεισφορές: Работа имела поддержку от Eisai Inc., Натли, штат Нью-Джерси, США, и Merck Sharp & Dohme LLC, дочерней компании Merck & Co., Inc., Рауэй, штат Нью-Джерси, США. Помощь в написании статьи была оказана Oxford PharmaGenesis Inc., Ньютаун, штат Пенсильвания, США. Статья имела финансирование от Eisai Inc., Натли, штат Нью-Джерси, США, и Merck Sharp & Dohme LLC, дочерней компании Merck & Co., Inc., Рауэй, штат Нью-Джерси, США. Пациентам, получавшим лечение в Мемориальном онкологическом центре им. Слоуна–Кеттеринга, оказывалась поддержка за счет гранта того же центра (P30 CA008748).
Πηγή: Cancer Urology; Том 20, № 1 (2024); 24-35 ; Онкоурология; Том 20, № 1 (2024); 24-35 ; 1996-1812 ; 1726-9776
Θεματικοί όροι: саркоматоидный компонент, lenvatinib, pembrolizumab, sunitinib, bone metastasis, liver metastasis, lung metastasis, sarcomatoid histology, ленватиниб, пембролизумаб, сунитиниб, метастаз в костях, метастаз в печени, метастаз в легких
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1810/1529; Choueiri T.K., Motzer R.J. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 2017;376:354–66. DOI:10.1056/NEJMra1601333; Motzer R., Alekseev B., Rha S.Y. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384:1289–300. DOI:10.1056/NEJMoa2035716; Dudani S., de Velasco G., Wells J.C. et al. Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival. JAMA Netw Open 2021;4:e2021869. DOI:10.1001/jamanetworkopen.2020.21869; Wei H., Miao J., Cui J. et al. The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database. Sci Rep 2021;11:17822. DOI:10.1038/s41598-021-97365-6; Hahn A.W., Lebenthal J., Genovese G. et al. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 2022;33:100640. DOI:10.1016/j.ctarc.2022.100640; Bianchi M., Sun M., Jeldres C. et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 2012;23:973–80. DOI:10.1093/annonc/mdr362; National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Kidney Cancer. Available at: https://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf (accessed April 31, 2023).; Yue G., Deyu L., Lianyuan T. et al. Clinical features and prognostic factors of patients with metastatic renal cell carcinoma stratified by age. Aging (Albany NY) 2021;13:8290–305. DOI:10.18632/aging.202637; Chen S.C., Kuo P.L. Bone metastasis from renal cell carcinoma. Int J Mol Sci 2016;17:987. DOI:10.3390/ijms17060987; Coleman R., Hadji P., Body J.J. et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2020;31:1650–63. DOI:10.1016/j.annonc.2020.07.019; Rathmell W.K., Rumble R.B., Van Veldhuizen P.J. et al. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. J Clin Oncol 2022;40:2957–95. DOI:10.1200/JCO.22.00868; Hamada S., Ito K., Kuroda K. et al. Clinical characteristics and prognosis of patients with renal cell carcinoma and liver metastasis. Mol Clin Oncol 2015;3:63–8. DOI:10.3892/mco.2014.432; Leibovich B.C., Blute M.L., Cheville J.C. et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97:1663–71. DOI:10.1002/cncr.11234; Bottiglieri A., Sepe P., Stellato M. et al. Optimal choice of adjuvant treatment for renal cell carcinoma following nephrectomy. Cancer Manag Res 2022;14:3071–81. DOI:10.2147/CMAR.S360441; Culp S.H., Tannir N.M., Abel E.J. et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 2010;116:3378–88. DOI:10.1002/cncr.25046; Gong J., Maia M.C., Dizman N. et al. Metastasis in renal cell carcinoma: biology and implications for therapy. Asian J Urol 2016;3:286–92. DOI:10.1016/j.ajur.2016.08.006; Motzer R.J., Banchereau R., Hamidi H. et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell 2020;38:803–17.e4. DOI:10.1016/j.ccell.2020.10.011; Choueiri T.K., Atkins M.B., Bakouny Z. et al. Summary from the first kidney cancer research summit, September 12–13, 2019: a focus on translational research. J Natl Cancer Inst 2021;113:234–43. DOI:10.1093/jnci/djaa064; Choueiri T.K., Powles T., Burotto M. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384:829–41. DOI:10.1056/NEJMoa2026982; Motzer R.J., Tannir N.M., McDermott D.F. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378:1277–90. DOI:10.1056/NEJMoa1712126; Motzer R.J., Penkov K., Haanen J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:1103–15. DOI:10.1056/NEJMoa1816047; Braun D.A., Bakouny Z., Hirsch L. et al. Beyond conventional immune-checkpoint inhibition – novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol 2021;18:199–214. DOI:10.1038/s41571-020-00455-z; Van Allen E.M., Choueiri T.K. Dissecting the immunogenomic biology of cancer for biomarker development. Nat Rev Clin Oncol 2021;18:133–4. DOI:10.1038/s41571-020-00461-1; Burke J.F., Sussman J.B., Kent D.M., Hayward R.A. Three simple rules to ensure reasonably credible subgroup analyses. BMJ 2015;351:h5651. DOI:10.1136/bmj.h5651; Ravi P., Bakouny Z., Schmidt A., Choueiri T.K. Novel therapeutic appro-aches and the evolution of drug development in advanced kidney cancer. Cancer J 2020;26:464–70. DOI:10.1097/PPO.0000000000000477; https://oncourology.abvpress.ru/oncur/article/view/1810